Feasibility of Semaglutide in Advanced Lung Disease

NCT05746039 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide is tolerable in people with advanced lung disease who also have obesity.

Status Recruiting Currently enrolling participants.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 8 people Planned (estimated).

Who can join Ages 18–80 · all sexes

Timeline Started 2024-01 · est. completion 2027-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05746039 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight? Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.

Treatments tested

Semaglutide Pen Injector also known as Ozempic Drug

Once weekly subcutaneous injection

Main thing measured	Tolerability
Sponsor	University of Pennsylvania
Conditions studied	Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05746039 ↗